Skip header and navigation

Refine By

30 records – page 1 of 3.

Abstracts from "Retrovir--an update of its use in HIV therapy". Satellite symposium of the IVth International Conference on AIDS. Stockholm, Sweden, 12 June 1988.

https://arctichealth.org/en/permalink/ahliterature8670
Source
J Acquir Immune Defic Syndr. 1988;1(6):616-20
Publication Type
Article
Date
1988
Source
J Acquir Immune Defic Syndr. 1988;1(6):616-20
Date
1988
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - drug therapy
Humans
Zidovudine - therapeutic use
PubMed ID
3225747 View in PubMed
Less detail

Aerosolized pentamidine as primary prophylaxis for Pneumocystis carinii pneumonia: efficacy, mortality and morbidity.

https://arctichealth.org/en/permalink/ahliterature7970
Source
AIDS. 1994 Jul;8(7):935-9
Publication Type
Article
Date
Jul-1994
Author
C. Lidman
O. Berglund
E. Tynell
S. Lindbäck
K. Elvin
Author Affiliation
Department of Infectious Diseases, Huddinge Hospital, Sweden.
Source
AIDS. 1994 Jul;8(7):935-9
Date
Jul-1994
Language
English
Publication Type
Article
Keywords
AIDS-Related Opportunistic Infections - epidemiology - mortality - prevention & control
Absenteeism
Acquired Immunodeficiency Syndrome - epidemiology
Adult
Aerosols
Disease Progression
Female
Follow-Up Studies
Hospitalization - statistics & numerical data
Humans
Male
Pentamidine - administration & dosage - therapeutic use
Pneumonia, Pneumocystis - epidemiology - mortality - prevention & control
Research Support, Non-U.S. Gov't
Risk factors
Sweden - epidemiology
Zidovudine - therapeutic use
Abstract
OBJECTIVE: Primary prophylaxis against Pneumocystis carinii pneumonia (PCP) for patients with HIV infection has been recommended by the Centers for Disease Control and Prevention. We evaluated alternatives to routine primary PCP prophylaxis with aerosolized pentamidine. METHODS: A total of 121 HIV-infected patients with CD4+ cell counts
Notes
Comment In: AIDS. 1995 Jan;9(1):1007893433
PubMed ID
7946102 View in PubMed
Less detail

AIDS patients' concerns at centre stage during Vancouver conference.

https://arctichealth.org/en/permalink/ahliterature226014
Source
CMAJ. 1991 Jul 15;145(2):151-2
Publication Type
Conference/Meeting Material
Date
Jul-15-1991
Source
Dimens Health Serv. 1991 Apr;68(3):6-7
Publication Type
Article
Date
Apr-1991

Canadian court upholds Glaxo's patent on AZT.

https://arctichealth.org/en/permalink/ahliterature191593
Source
Can HIV AIDS Policy Law Rev. 2001;6(1-2):53-7
Publication Type
Article
Date
2001
Author
R. Elliott
Source
Can HIV AIDS Policy Law Rev. 2001;6(1-2):53-7
Date
2001
Language
English
French
Publication Type
Article
Keywords
Canada
Drug Industry - legislation & jurisprudence
Drugs, Generic
HIV Infections - drug therapy
Humans
Patents as Topic - legislation & jurisprudence
Reverse Transcriptase Inhibitors - therapeutic use
Zidovudine - therapeutic use
Abstract
In October 2000, the Federal Court of Appeal issued the latest ruling in the ongoing dispute over the validity of Glaxo's Canadian patent for AZT, upholding Glaxo's patent but narrowing the scope of the claims it could validly make. The decision is now on appeal to the Supreme Court of Canada.
PubMed ID
11837029 View in PubMed
Less detail

Changing incidence of HIV-induced brain lesions in Oslo, 1983-1994: effects of zidovudine treatment.

https://arctichealth.org/en/permalink/ahliterature7861
Source
AIDS. 1995 Oct;9(10):1165-9
Publication Type
Article
Date
Oct-1995
Author
J. Maehlen
O. Dunlop
K. Liestøl
J H Dobloug
A K Goplen
A. Torvik
Author Affiliation
Department of Pathology, Ulleval University Hospital, Oslo, Norway.
Source
AIDS. 1995 Oct;9(10):1165-9
Date
Oct-1995
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - complications - drug therapy - mortality
Adult
Aged
Antiviral agents - therapeutic use
Brain - pathology
Brain Diseases - etiology - pathology
Cytopathogenic Effect, Viral
Encephalitis, Viral - mortality - prevention & control
Female
Giant Cells - drug effects - pathology
Humans
Male
Middle Aged
Norway
Regression Analysis
Research Support, Non-U.S. Gov't
Survival Rate
Zidovudine - therapeutic use
Abstract
OBJECTIVE: To investigate the relation between HIV-induced brain lesions, zidovudine (ZDV) treatment and survival length in a well-defined population of HIV-positive patients. METHODS AND PATIENTS: Ulleval Hospital has the responsibility for treating all AIDS patients from the city of Oslo except haemophiliac patients. The patient population in this autopsy study comprised all adult AIDS patients in Oslo who were treated at our hospital and died during 1983-1994 (n = 171). This represents 86% of all adult AIDS patients from Oslo who died during the same period. Full autopsy, including neuropathological examination of the brain and spinal cord, was performed on 128 (75%) of those who died. RESULTS: No significant differences were found between autopsy and non-autopsy cases with regard to sex, age, risk groups, survival length or ZDV treatment. In the autopsy material, multinucleated giant cells (MGC) in brain tissue were found in 29 cases and diffuse damage of white matter in 52 cases. Analysis shows that ZDV (600 mg per day) reduced the incidence of these brain lesions, but only if continued until death. A second finding was an increased incidence of HIV-induced brain lesions for those with long-term survival. Together these observations may explain a substantial part of the time-trend in the incidence of MGC in Oslo. MGC were frequent (40%) during the first years of the epidemic, although survival length was short in this period. The incidence fell markedly around the time ZDV was introduced and later remained low in those using ZDV until death. The incidence of MGC has, however, increased during the later years, the new cases mainly occurring in patients who had discontinued ZDV use. CONCLUSION: If continued until death, ZDV can reduce the incidence of HIV-induced brain lesions in AIDS patients. When ZDV treatment is terminated a rapid increase occurs in the incidence of HIV encephalitis.
PubMed ID
8519453 View in PubMed
Less detail

Costs and benefits of screening pregnant women for HIV.

https://arctichealth.org/en/permalink/ahliterature210574
Source
CMAJ. 1996 Nov 15;155(10):1387
Publication Type
Article
Date
Nov-15-1996
Author
H. Bueckert
Source
CMAJ. 1996 Nov 15;155(10):1387
Date
Nov-15-1996
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - prevention & control - transmission
Female
Health Care Costs
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical - prevention & control
Mass Screening - economics
Ontario
Pregnancy
Pregnancy Complications, Infectious - prevention & control
Pregnant Women
Voluntary Programs
Zidovudine - therapeutic use
Notes
Cites: N Engl J Med. 1994 Nov 3;331(18):1173-807935654
Cites: Arch Pediatr Adolesc Med. 1995 May;149(5):489-967735400
Comment On: CMAJ. 1996 Jul 1;155(1):53-48673985
PubMed ID
8943920 View in PubMed
Less detail

The effect of zidovudine on platelet count in HIV-infected individuals.

https://arctichealth.org/en/permalink/ahliterature103620
Source
J Acquir Immune Defic Syndr. 1990;3(6):565-70
Publication Type
Article
Date
1990
Author
J S Montaner
T. Le
M. Fanning
K. Gelmon
C. Tsoukas
J. Falutz
M. O'Shaughnessy
M A Wainberg
J. Ruedy
Author Affiliation
Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.
Source
J Acquir Immune Defic Syndr. 1990;3(6):565-70
Date
1990
Language
English
Publication Type
Article
Keywords
Canada
HIV Infections - blood - complications - drug therapy
Humans
Male
Multicenter Studies as Topic
Platelet Count - drug effects
Thrombocytopenia - complications - drug therapy
Zidovudine - therapeutic use
Abstract
Seventy-four HIV-infected homosexual males belonging to CDC groups IIB, III, and IVC2 were treated with increasing doses of zidovudine within the Multicentre Canadian AZT Trial. Following a 3 week observation period, consenting volunteers received 600 mg/day for 18 weeks, 900 mg/day for 9 weeks, and 1,200 mg/day for 9 weeks. This was followed by a 6 week washout period after which zidovudine was restarted at 1,200 mg/day for 18 weeks. Patients were followed for a total of 63 weeks. Every 3 weeks they underwent a full clinical and laboratory assessment. For the purpose of this analysis, subjects were divided according to the mean initial platelet value (greater than or equal to 150,000 or less than 150,000/L) into normals (n = 57) and thrombocytopenics (n = 12), respectively. Analysis of variance was used to compare the mean platelet values at each zidovudine dose. All comparisons were made against baseline values. Zidovudine increased platelet counts in normal and thrombocytopenic subjects. The magnitude of this effect varied depending on the baseline platelet count. Among normals, the platelet count increased from 241,000 +/- 45,000/L at baseline to 261,000 +/- 51,000/L (p less than 0.01). while receiving 600 mg/day of zidovudine. This effect was self-limited, reaching a peak by week 3. The platelet count decreased to baseline values despite increasing the dose of zidovudine to 900 or 1,200 mg/day. The platelet count further decreased to 218,000 +/- 43,000/L during the washout phase (washout vs. 1,200 mg, p less than 0.01).2+ not found to be dose related. The platelet count decreased to 101,000 +/- 34,000/L during the washout phase (washout vs. 1,200 mg/day, p less than 0.07).(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed ID
2187071 View in PubMed
Less detail

[Genetic characteristics of HIV-1 subtype G reverse transcriptase gene].

https://arctichealth.org/en/permalink/ahliterature164844
Source
Vopr Virusol. 2007 Jan-Feb;52(1):17-23
Publication Type
Article
Author
A S Pazilin
S R Saukhat
A B Shemshura
L D Nikitina
M M Garaev
Source
Vopr Virusol. 2007 Jan-Feb;52(1):17-23
Language
Russian
Publication Type
Article
Keywords
Amino Acid Sequence
Disease Outbreaks
Drug Resistance, Viral - genetics
HIV Infections - drug therapy - epidemiology - virology
HIV Reverse Transcriptase - genetics
HIV-1 - classification - genetics
Humans
Molecular Sequence Data
Mutation
Phylogeny
Reverse Transcriptase Inhibitors - administration & dosage
Russia - epidemiology
Sequence Alignment
Species Specificity
Zidovudine - therapeutic use
Abstract
The paper presents data of a study of the structure of reverse transcriptase gene in the population infected with HIV subtype G formed during the 1989 HIV infection outbreak in the North-Caucasian region. The authors analyzed 3 samples obtained in 1993-1994 and 17 samples taken in 2000-2001. The phylogenetic analysis indicated that polymerase of the test virus variants belonged to HIV-1 subtype G. The mutations occurring with azidothymidine therapy did not differ from those in subtype B. Analysis of the mutations of resistance to other nucleoside and non-nucleoside reverse transcriptase inhibitors did not show great differences from subtype B either.
PubMed ID
17338229 View in PubMed
Less detail

30 records – page 1 of 3.